Understanding how altered cell energy drives blood cell changes in clonal hematopoiesis
Aberrant glycolysis as a driver of mutant HSPC expansion in clonal hematopoiesis
This project looks at how changes in cell energy help certain blood cells grow abnormally in a condition called clonal hematopoiesis, which can affect heart health.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project ID | NIH-11121874 on NIH RePORTER |
What this research studies
Clonal hematopoiesis (CH) is a condition where some of your blood stem cells develop mutations and start to multiply more than they should. These abnormal cells can then contribute to health issues like heart disease and may increase the risk of blood cancers. We believe that a combination of inflammation and changes in how these cells produce energy helps them grow. Our work uses models to understand these energy changes, hoping to find new ways to stop the abnormal cell growth.
Who could benefit from this research
Good fit: Patients with clonal hematopoiesis, especially those with related conditions like cardiovascular disease or a history of genotoxic exposures, may eventually benefit from this research.
Not a fit: Patients without clonal hematopoiesis or related conditions would not directly benefit from this specific research focus.
Why it matters
Potential benefit: If successful, this work could lead to new treatments that slow or stop the progression of clonal hematopoiesis, potentially reducing the risk of cardiovascular disease and blood cancers.
How similar studies have performed: While the link between inflammation, metabolism, and clonal hematopoiesis is an active area of investigation, this specific approach of targeting aberrant glycolysis as a driver is a novel and promising direction.
Where this research is happening
Aurora, UNITED STATES
- University of Colorado Denver — Aurora, United States (Active)
Researchers
- Principal investigator: Pietras, Eric M — University of Colorado Denver
- Study coordinator: Pietras, Eric M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.